[ad_1]
A new migraine drug is entering an already crowded market, but it could mean fewer headaches for some patients.
The pharmaceutical group Eli Lilly announced Thursday that the FDA had approved its drug Emgality.
This is a monthly injection designed to prevent migraines in adults and to reduce the number of migraine days available to patients. The debilitating neurological disorders affect more than 30 million Americans.
Emgality is the third drug of its kind recently approved by federal regulators, joining a competitive market within the pharmaceutical industry.
That's why Lilly and the drug makers behind the other two drugs are offering their product at little or no cost to some insured migraine sufferers for a while.
And this could save a lot of money for patients in the long run. The catalog price for Emgality is $ 6,900 a year, which is in the same range as the other two injections.
Some analysts predict that competition may soon lower that price further, with the new class of drugs benefiting about 15 million Americans.
Equality is also about to be approved in the European Union.
[ad_2]
Source link
